Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer

Keyphrases

• Epidermal Growth Factor Receptor 100%
• Previously Treated 100%
• Non-small Cell Lung Cancer (NSCLC) 100%
• Phase II Trial 100%
• Cetuximab 100%
• Response Rate 80%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 40%
• Time to Progression 40%
• Tumor 20%
• Disease Progression 20%
• Disease Pattern 20%
• Diarrhea 20%
• Overall Survival 20%
• Phase II Study 20%
• Patient Characteristics 20%
• Adenocarcinoma 20%
• Patient Demographics 20%
• Median Time 20%
• Smoking Status 20%
• Prior Chemotherapy 20%
• Stable Disease 20%
• Heavily Pretreated Patients 20%
• Chemotherapy Regimen 20%
• Anaphylactic Reaction 20%
• Disease Control Rate 20%
• Erlotinib 20%
• Median Survival Time 20%
• Pemetrexed 20%
• Docetaxel 20%
• Disease Rate 20%
• Positive Development 20%
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) 20%
• Number of Prior Regimens 20%
• Acne-like Rash 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Epidermal Growth Factor Receptor 100%
• Non Small Cell Lung Cancer 100%
• Phase II Trials 100%
• Cetuximab 100%
• Diseases 60%
• Neoplasm 20%
• Diarrhea 20%
• Overall Survival 20%
• Chemotherapy 20%
• Adenocarcinoma 20%
• Disease Exacerbation 20%
• Patient History of Chemotherapy 20%
• Rash 20%
• Anaphylaxis 20%
• Erlotinib 20%
• Median Survival Time 20%
• Pemetrexed 20%
• Docetaxel 20%
• Acne 20%